GSK buys respiratory drug maker Aiolos in $1.4bn deal

GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

The deal provides GSK with access to Aiolos' AIO-001, a drug ready to enter phase II clinical development for the treatment of adult patients with asthma, with potential for additional indications including chronic rhinosinusitis with nasal polyps.

GSK will pay $1bn upfront, with an extra $400m in milestone payments if targets are met.

Founded in 2023, Aiolos Bio is a San Francisco, USA and London, UK-based clinical-stage, private, biopharmaceutical company focused on treating respiratory disease.

Reporting by Frank Prenesti for Sharecast.com